Pretransplant FLT3-ITD MRD Assessed by High-sensitivity PCR-NGS Determines Posttransplant Clinical Outcome

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Aug 12

PMID 35960851

Authors

Sun Loo

Richard Dillon

Adam Ivey

Natasha S Anstee

Jad Othman

Ing Soo Tiong

Nicola Potter

Jelena Jovanovic

Manohursingh Runglall

Chyn Chua Chong

Ashish Bajel

David Ritchie

Kelli Gray

Zhi Han Yeoh

Michelle McBean

Amanda Gilkes

Ian Thomas

Sean Johnson

Nigel H Russell

Andrew H Wei

Affiliations

Soon will be listed here.

Citing Articles

Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia.

Gang M, Othus M, Walter R Cells. 2025; 14(4).

PMID: 39996762 PMC: 11853423. DOI: 10.3390/cells14040290.

Impact of myelodysplasia-related and additional gene mutations in intensively treated patients with -mutated AML.

Cocciardi S, Saadati M, Weiss N, Spath D, Kapp-Schwoerer S, Schneider I Hemasphere. 2025; 9(1):e70060.

PMID: 39816531 PMC: 11733593. DOI: 10.1002/hem3.70060.

Quantification of the FLT3 internal tandem duplication is a reliable marker for monitoring measurable residual disease in acute myeloid leukemia with FLT3-ITD mutations.

Wang M, Huang S, Huang Y, Zhang J, Li H, Ge S Bone Marrow Transplant. 2024; 60(3):412-414.

PMID: 39658655 DOI: 10.1038/s41409-024-02495-w.

Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient.

Heuser M, Shahswar R Hematology Am Soc Hematol Educ Program. 2024; 2024(1):158-167.

PMID: 39644001 PMC: 11665733. DOI: 10.1182/hematology.2024000542.

Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?.

El Chaer F, Perissinotti A, Loghavi S, Zeidan A Leukemia. 2024; 39(1):1-7.

PMID: 39496917 DOI: 10.1038/s41375-024-02458-6.

References

Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A . Molecular MRD status and outcome after transplantation in NPM1-mutated AML. Blood. 2020; 135(9):680-688. PMC: 7059484. DOI: 10.1182/blood.2019002959. View

Ivey A, Hills R, Simpson M, Jovanovic J, Gilkes A, Grech A . Assessment of Minimal Residual Disease in Standard-Risk AML. N Engl J Med. 2016; 374(5):422-33. DOI: 10.1056/NEJMoa1507471. View

Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik V, Paschka P, Roberts N . Genomic Classification and Prognosis in Acute Myeloid Leukemia. N Engl J Med. 2016; 374(23):2209-2221. PMC: 4979995. DOI: 10.1056/NEJMoa1516192. View

Altman J, Perl A, Hill J, Rosales M, Bahceci E, Levis M . The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation-positive relapsed/refractory acute myeloid leukemia. Cancer Med. 2020; 10(3):797-805. PMC: 7897940. DOI: 10.1002/cam4.3652. View

Helbig G, Koclega A, Wieczorkiewicz-Kabut A, Wozniczka K, Kopinska A, Boral K . Pre-transplant FLT3/ITD status predicts outcome in FLT3-mutated acute myeloid leukemia following allogeneic stem cell transplantation. Ann Hematol. 2020; 99(8):1845-1853. PMC: 7340651. DOI: 10.1007/s00277-020-04026-1. View

Bibault J, Figeac M, Helevaut N, Rodriguez C, Quief S, Sebda S . Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015; 6(26):22812-21. PMC: 4673201. DOI: 10.18632/oncotarget.4333. View

Hourigan C, Dillon L, Gui G, Logan B, Fei M, Ghannam J . Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease. J Clin Oncol. 2019; 38(12):1273-1283. PMC: 7164487. DOI: 10.1200/JCO.19.03011. View

Thol F, Kolking B, Damm F, Reinhardt K, Klusmann J, Reinhardt D . Next-generation sequencing for minimal residual disease monitoring in acute myeloid leukemia patients with FLT3-ITD or NPM1 mutations. Genes Chromosomes Cancer. 2012; 51(7):689-95. DOI: 10.1002/gcc.21955. View

Burchert A, Bug G, Fritz L, Finke J, Stelljes M, Rollig C . Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With -Internal Tandem Duplication Mutation (SORMAIN). J Clin Oncol. 2020; 38(26):2993-3002. DOI: 10.1200/JCO.19.03345. View

10.

Blombery P, Jones K, Doig K, Ryland G, McBean M, Thompson E . Sensitive NPM1 Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory. Arch Pathol Lab Med. 2018; 142(5):606-612. DOI: 10.5858/arpa.2017-0229-OA. View

11.

Blatte T, Schmalbrock L, Skambraks S, Lux S, Cocciardi S, Dolnik A . getITD for FLT3-ITD-based MRD monitoring in AML. Leukemia. 2019; 33(10):2535-2539. PMC: 8075860. DOI: 10.1038/s41375-019-0483-z. View

12.

Stone R, Mandrekar S, Sanford B, Laumann K, Geyer S, Bloomfield C . Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017; 377(5):454-464. PMC: 5754190. DOI: 10.1056/NEJMoa1614359. View

13.

Gaballa S, Saliba R, Oran B, Brammer J, Chen J, Rondon G . Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017; 92(4):331-337. PMC: 5352512. DOI: 10.1002/ajh.24632. View